New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
09:31 EDTTLOGTetraLogic has new opportunities, says Needham
Needham believes that TetraLogic's Phase I study of birinapant in patients chronically infected with hepatitis B opens up new opportunities for the company. The firm expects the stock to be boosted by data, expected in Q3, from a Phase I/II study in combination with a TRAIL receptor agonist in breast cancer. The firm keeps a Buy rating on the shares.
News For TLOG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
07:14 EDTTLOGTetraLogic initiates SHAPE Phase 2 clinical trial
TetraLogic Pharmaceuticals announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with early stage cutaneous T‑cell lymphoma, or CTCL. SHAPE has been evaluated in a randomized, dose escalation, placebo-controlled Phase 1 clinical trial in early-stage CTCL subjects that met safety endpoints and demonstrated clinical activity. Four of fifteen patients receiving SHAPE attained an objective response as measured by a greater than 50% improvement in their Composite Assessment of Index Lesion Severity, or CAILS, score during and after 28 days of dosing. No placebo patients responded. The randomized Phase 2 trial will be conducted in approximately sixty subjects with Stage IA-IIA CTCL. The objectives of the Phase 2 clinical trial are to evaluate the dose, clinical effect at 6 months, time to response, and tolerability of treatment of greater than 2% body surface area.
December 17, 2014
09:05 EDTTLOGTetraLogic sell-off yesterday overdone, says Needham
Subscribe for More Information
December 16, 2014
12:26 EDTTLOGOn The Fly: Midday Wrap
Subscribe for More Information
07:12 EDTTLOGTetraLogic provides update on ovarian cancer study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use